Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, the company will soon have to halt sales of its cheaper alternative. That said,

Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so significant it could shift GDP.

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs like Wegovy or Zepbound. Her weight dropped so much that researchers reduced her dose of the treatment, called retatrutide. Still, she continued to feel too nauseous, so she decided by herself to start skipping every other dose.

The Medicines and Healthcare Products Regulatory Agency (MHRA) revealed in association with the use of GLP-1RA receptor agonist drugs such as Mounjaro, Wegovy and Ozempic, up to January 31.

Consumer Reports looked at how weight loss drugs and possible side effects in older adults. When teenage Abigail Kwartekaa Quartey decided to become a professional boxer – an unlikely choice for a young woman in a working class neighborhood in Ghana – her family begged her to stop training.